| Literature DB >> 35414772 |
Yu-Jing Zhang1, Li Shen2, Tao Zhang3, Kahindo P Muyayalo1, Jing Luo1, Gil Mor1,4, Ai-Hua Liao1.
Abstract
A successful pregnancy requires the maternal immune system to tolerate an allogeneic fetus. The incidence of preeclampsia and other complications related to impaired fetal tolerance is lower during the second pregnancy than during the first pregnancy. At the same time, compared with normal pregnant women in the previous pregnancy, patients with pregnancy complications in the previous pregnancy also have an increased risk of the disease when they become pregnant again. This difference may be related to the immunological memory of pregnancy. Regulatory T cells (Tregs) are immunosuppressive CD4+ T cells that play a predominant role in maintaining immune tolerance. In addition, Tregs possess immunological memory properties, including fetal or paternal-specific memory Tregs and Tregs expressing memory cell makers, forming an immunoregulatory memory against fetal antigens. In this review, we provide an overview of the characteristics of memory Tregs in pregnancy, evidence regarding the existence of memory Tregs in human pregnancy, as well as in mouse models. We also discuss the mechanism of memory Tregs induction, maintenance, and action. In addition, we described their changes during the first pregnancy, second pregnancy, postpartum, and pathological pregnancy in order to provide new targets for the diagnosis and treatment of pregnancy related diseases. © The author(s).Entities:
Keywords: gestational diabetes mellitus; memory; preeclampsia; pregnancy; regulatory T cells
Mesh:
Substances:
Year: 2022 PMID: 35414772 PMCID: PMC8990478 DOI: 10.7150/ijbs.70629
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 10.750
Summary of the studies on memory Tregs in pregnancy
| Grouping | Markers of memory Tregs | Sampling times and sources for memory Tregs | Proportion of memory Tregs | Main conclusions | References |
|---|---|---|---|---|---|
| ♀B6 ×♂Balb/c-2W1S; ♀B6 ×♂B6-2W1S; ♀B6 ×♂Balb/c. | CD4+2W1S+ Foxp3+ | Virgin; E 11.5; E 18.5; PP 2; PP 14; PP 30; PP 100 (in spleen and lymph nodes) | (Percentage of Foxp3+ among 2W1S+CD4+ cells) Virgin: 7%; E11.5: 21.1%; E18.5: 45.1%; PP2: 60.1%; PP14: 20.1%; PP30: 19.6%; PP100: 18.4%. | Pregnancy imprints Foxp3+CD4 cells to maintain the protective regulatory memory to the fetal antigen. |
|
| ♀Balb/c ×♂B6 | amTregs: CD4+Foxp3+CD44highCD62Llow | dpi 1; dpi 4; dpi 6; dpi 7; dpi 10; dpi 12 (in dLN and ndLN) | In dLN, the frequency of amTregs from dpi 6 to dpi 10 increased. | Early recruitment of amTregs in uterine dLNs was triggered by embryo implantation. |
|
| ♀Foxp3DTR ×♂BALB/C; Tregs depletion with DT. | Tregs: CD45+CD3+CD4+CD25+Foxp3+ | Delivery; 1w, 2w, and 3 w of postpartum (in decidua, myometrium, peripheral blood, placenta) | None. | The enhanced Tregs expansion during the second pregnancy was related to maternal-fetal tolerance, as well as the health of the newborn. |
|
| Patients undergoing IVF / ICSI: Pregnancy group (n = 36); Nonpregnant group (n = 160). | DR+ Tregs: D45RA-HLA-DR+ Tregs; DR- Tregs: CD45RA-HLA-DR- Tregs | 1 hour before embryo transfer; 7w; 14w; 21w; 28w (in peripheral blood) | 1 hour before embryo transfer in pregnancy group (Percentage in total Tregs); DR+ Tregs: 27.0%; DR- Tregs: 30.1%. | Compared with that in women with successful pregnancy, the percentage of DR-Tregs was increased in non-pregnant women. |
|
| Healthy pregnant women (n = 64); Dietary-adjusted GDM ( n = 21); Insulin-dependent GDM (n = 40). | DR- Tregs: CD45RA-HLA-DR-Tregs; DRlow+ Tregs: CD45RA-HLA-DRlow+ Tregs; DRhigh+ Tregs: CD45RA-HLA-DRhigh+Tregs. | 24 - 41 w (in peripheral blood) | Healthy pregnant group (Percentage in total Tregs): DR+ Treg: 22.8%; DRlow+ Treg: 20.3%; DRhigh+ Treg: 2.5%; DR-Treg: 29.9% . | ① The percentage of DR-Tregs was significantly higher in patients with dietary-adjusted GDM than that in healthy pregnancies; ② The percentages of DRlow+ Tregs and DRhigh+ Tregs were significantly higher in patients with insulin-dependent GDM than those in healthy pregnancies. |
|
| Non-pregnant women (n=31); Healthy pregnant women (n=169); PE ( n = 37). | CD31+ memory Tregs: CD45RA-CD31+ Tregs; CD31- memory Tregs: CD45RA-CD31- Tregs (Tregs: CD4+CD127low+/-Foxp3+). | 1st trimester; 2nd trimester; 3rd trimester; term | 3rd trimester (Percentage in total Tregs): CD31+memory Tregs: 4%; CD31-memory Tregs: 66%. | ① At the beginning of pregnancy, RTE-Tregs differentiated into CD31-memory Tregs and were maintained until term delivery. ② In PE group, CD45RA-CD31+ memory Tregs were significantly increased. |
|
| Non-pregnant fertile women (n = 31); Healthy pregnant women (n = 135) ; PE (n = 27); HELLP (n = 15) ; CI (n = 30); PL (n = 24). | CD45RA-HLA-DR- Tregs; CD45RA-HLA-DRlow+ Tregs; CD45RA-HLA-DRhigh+ Tregs. | 24-42 weeks' gestation | Healthy pregnant group (Percentage in Tregs): CD45RA-HLA-DR-Treg: 30.4%; CD45RA-HLA-DRlow+Treg: 23.6%; CD45RA-HLA-DRhigh+Treg: 4.8%. | PE and PL were characterized by distinct Treg subsets accompanied by a significant decrease in their suppressive activity. |
|
Note: Tregs not specifically defined in the table are CD4+CD127low+/-CD25+Foxp3+. amTregs: activated/memory Tregs; CI: cervical insufficiency; dLN: draining lymph node; dpi: day postimplantation; DT: diphtheria toxin; DTR: diphtheria toxin receptor; DR+ Tregs: HLA-DR+ memory Tregs; DR- Tregs: HLA-DR- memory Tregs; DRhigh+ Tregs: HLA-DRhigh+ memory Tregs; DRlow+ Tregs: HLA-DRlow+ memory Tregs; E: embryonic day; Foxp3+: forkhead box P3+; GDM: gestational diabetes mellitus; HELLP: haemolysis-elevated liver enzyme levels-low platelet count syndrome; IVF/ICSI: in vitro fertilization/intracytoplasmic sperm injection; ndLN: non-dLN; PE: preeclampsia; PL: preterm labour necessitating preterm delivery; PP: post-partum day; RTE-Tregs: recent thymic emigrant-regulatory T-cells; Tregs: Regulatory T cells; w: weeks of gestation; 1st trimester: the first trimester; 2nd trimester: the second trimester; 3rd trimester: the third trimester.
Changes of memory Tregs in healthy and pathological pregnancies
| Memory Tregs | Mouse or human | During normal pregnancy | PE | Dietary GDM | Insulin GDM | HELLP | PL | Failure of ART | References | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st trimester | 2nd trimester | 3rd trimester | |||||||||
| amTregs | mouse | ↑ |
| ||||||||
| fetal-specific Tregs | mouse | ↑ | ↑ | ↑ |
| ||||||
| DR+ Tregs | human | ↑ | ↓ | ↓ |
| ||||||
| DR- Tregs | human | ↑ | ↑ | ↑ | ↑ | ||||||
| DRlow+ Tregs | human | ↓ | ↑ | ↑ | ↑ | ||||||
| DRhigh+ Tregs | human | ↓ | ↑ | ↑ | ↑ | ||||||
| CD31+ memory Tregs | human | ↓ | ↑ |
| |||||||
| CD31- memory Tregs | human | ↑ |
| ||||||||
Note: amTregs: activated/memory Tregs (CD4+Foxp3+CD44highCD62Llow); ART: Assisted Reproductive Technology; CD31+ memory Tregs: (CD45RA-CD31+ Tregs); CD31- memory Tregs: (CD45RA-CD31- Tregs); DR+ Tregs: HLA-DR+ memory Tregs (CD45RA-HLA-DR+ Tregs); DR- Tregs: HLA-DR- memory Tregs (CD45RA-HLA-DR- Tregs); DRlow+ Tregs: HLA-DRlow+ memory Tregs (CD45RA-HLA-DRlow+ Tregs); DRhigh+ Tregs: HLA-DRhigh+ memory Tregs (CD45RA-HLA-DRhigh+ Tregs); GDM: gestational diabetes mellitus; HELLP: haemolysis-elevated liver enzyme levels-low platelet count syndrome; PE: preeclampsia; PL: irresistible preterm delivery; Tregs: Regulatory T cells; 1st trimester: the first trimester; 2nd trimester: the second trimester; 3rd trimester: the third trimester.
Figure 1The induction and characteristics of memory Tregs in pregnancy. (A) During pregnancy, Tregs in maternal peripheral blood may be induced to generate memory Tregs by paternal semen, fetal microchimerism, fetal cells, and cytokines such as IL-2 and IL-7. (B-C) Previous studies have divided memory Tregs into different subsets in mice and humans. In pregnant mice, memory Tregs were divided into fetal-specific Tregs and activated/memory Tregs (CD4+Foxp3+CD44highCD62Llow). Among them, fetal-specific Tregs may be generated outside the thymus, and they secreted IFN-γ reduced and exhibited a state of anergy (B). In pregnant women, memory Tregs were divided into HLA-DR+ memory Tregs (CD45RA-HLA-DR+ Tregs), HLA-DR- memory Tregs (CD45RA-HLA-DR- Tregs), HLA-DRlow+ memory Tregs (CD45RA-HLA-DRlow+ Tregs), HLA-DRhigh+ memory Tregs (CD45RA-HLA-DRhigh+ Tregs), CD31+ memory Tregs (CD45RA-CD31+ Tregs) and CD31- memory Tregs (CD45RA-CD31- Tregs) (C). IL, interleukin; TGF-β, transforming growth factor-β; Tregs, regulatory T cells; Foxp3, forkhead box P3; CCR, chemokine receptor; IFN-γ, interferon-γ.